AAIFNC 2026 Annual Symposium
The 2026 Bridges to Understanding program will provide continuing medical education on Mast Cells, Asthma, Drug and Food Allergy and AI in Allergy/Immunology.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Allergy, Asthma & Immunology Foundation of Northern California (AAIFNC). The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 6.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 6.25 contact hours.
No commercial support was received for this activity.
Target Audience
Practicing allergists
Primary care physicians
Allied healthcare professionals
Learning Objectives
At the conclusion of this activity, learners should be able to…
1. Appraise current and emerging therapies, including oral and intralymphatic immunotherapy, in terms of safety, adherence, and long-term outcomes compared to strict avoidance.
2. Propose strategies for timely specialist referral, multidisciplinary collaboration, and patient education to optimize biologic use, adherence, and long-term asthma outcomes.
3. Describe the differential diagnosis in patients being worked up for mast cell disorders
2026 AAIFNC Annual Symposium "Bridges to Understanding"
San Francisco CA
April 18, 2026
GENERAL SESSION ~ Nikko Ballroom I & II
EXHIBITS AND COFFEE BREAKS ~ Nikko Ballroom III
8:15AM-8:20AM Program Introduction & Welcome, Steve Machtinger, MD and Kristina Philpott, MD
Session Moderators: Steve Machtinger, MD and Kristina Philpott, MD
8:20AM-9:05AM Systemic Mastocytosis: Clinical Cases and Review of the Literature, Dayne Voelker, MD
9:05AM-9:50AM Mast Cell Activation Syndromes, Matthew P. Giannetti, MD
9:50AM-10:35AM When an “Eosinophilic” Disease is Actually Caused by Mast Cells: Update on Pathogenic Mechanisms of Nasal Polyposis, Larry Borish, MD
10:35AM-10:50AM Panel Discussion and Q&A
10:50AM-11:20AM Exhibits, Posters, Coffee Break
11:20AM-12:10PM Comparative Effects of Biologics for Severe and Difficult-to-Treat Asthma / Q & A, Giselle S. Mosnaim, MD, MS
12:10PM-1:00PM Solving Food Allergy Diagnostic Dilemmas: Can You Crack the Case? / Q & A, Scott H. Sicherer, MD
1:00PM-2:00PM Lunch Break & Exhibits
2:00PM-2:50PM Practical Approaches to Aspirin & NSAID/Aspirin Hypersensitivity / Q & A, Tanya M. Laidlaw, MD
2:50PM-3:40PM AI in Medicine: Integrated Intelligence or Illusory Imitation? / Q & A, Jonathan H. Chen, MD, PhD
3:40PM-4:00PM Q&A
4:00PM-4:10PM Acknowledgements & Wrap-Up, Steve Machtinger, MD – AAIFNC President
All relevant financial relationships with ineligible companies have been mitigated.
Larry Borish, MD – Speaker
Consultant: Novartis
Researcher: Adovate, Regeneron, Sanofi
Matthew P. Giannetti, MD – Speaker
Consultant: Blueprint, Cogent, Inmagene, Novartis, Palindome Therapeutics, Solu Therapeutics
Giselle Mosnaim, MD, MS – Speaker
Advisor: Amgen, AstraZeneca, Chiesi, Eli Lilly, Genentech, GSK, Jasper, Novartis, Regeneron, Sanofi, Teva
Consultant: Incyte, Regeneron, Sanofi
Speaker: Amgen, AstraZeneca, Chiesi, Novartis, Regeneron, Sanofi
Scott H. Sicherer, MD – Speaker
Researcher: Pfizer, Regeneron
Kristina H. Philpott, MD – Planner, Moderator
Stock/stock options: Amgen, Boston Scientific, Stryker, Thermo Fisher, Eli Lilly, GSK, Merck, Zoetis
Gregory Bensch, MD – Planner
Advisor: Aimmune, AstraZeneca, Dermavant, Sanofi/Regeneron
Consultant: Sanofi/Regeneron
Speaker: Aimmune, AstraZeneca, Blueprint, Incyte, Sanofi/Regeneron, Teva
The following have no relevant financial relationships with ineligible companies to disclose:
Jonathan H. Chen, MD, PhD – Speaker
Tanya M. Laidlaw, MD - Speaker
Dayne Voelker, MD – Speaker
Steve Machtinger, MD – Planner, Moderator
Javaid M. Khan, DO – Planner
Sean McGhee, MD, PhD – Planner
Rose Monahan, MD – Planner
Dai Park, MD – Planner
Michelle Huffaker, MD – Planner
Sarah Pederson, RN – Planner
Karol Anderson – Planner
Available Credit
- 6.25 AMA PRA Category 1 Credit™
- 6.25 Attendance
- 6.25 CBRN

Facebook
X
LinkedIn
Forward